Compare ING Groep NV (ING) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Medpace Holdings Inc — how do they compare? ING Groep NV trades at $33.17 (market cap $92.65B), while Medpace Holdings Inc trades at $534.38 (market cap $15.08B). The key difference: ING Groep NV is far larger — about 6.1× Medpace Holdings Inc's market cap, and ING Groep NV pays a 3.93% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| ING | MEDP | |
|---|---|---|
Market Cap | $92.65B | $15.08B |
Sector | Financials | Technology |
52-Week High | $33.31 | $620.59 |
52-Week Low | $22.71 | $308.88 |
Dividend Yield | 3.93% | — |
Enterprise Value | — | $14.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $32.13, down 0.62% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.63, beating expectations of $0.60, continuing a trend of earnings beats. Revenue for 2025 reached $22.90 billion with a net income margin of 27.84%. Recent strategic moves include a stake acquisition in Spain's Singular Bank and the rollout of a global subscription banking model to diversify revenue streams.
The outlook for ING is positive, supported by strong analyst consensus with 62.5% buy ratings and intrinsic value estimates around $34 from DCF analysis. Opportunities include European banking sector strength and net interest income upside from potential ECB rate hikes. Key risks involve persistent negative operating cash flow trends and competitive pressures in digital banking. The stock appears fairly valued with a P/E of 12.96 and P/B of 1.6.
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
